By Nigam Arora & Dr. Natasha Arora
39.5% Profit In One Day
The Chart
- The chart shows when Arora buy signal was given.
- The signal indicated that MorphoSys had become a buyout target.
- To control risk, the signal also provided a stop loss and recommended quantity.
- The signal also provided a target zone.
- The chart shows the move up on the buyout.
Opportunities In Cancer Cures
The reason Novartis was willing to pay such a high price for MorphoSys was MorphoSys’s drug that is under development called pelabresib. Pelabresib may be a game changer in myelofibrosis and knotty lymphomas.
Lucrative Space
Unrivaled Record
Variety
- Iconic American steel company
- A natural gas producer
- Software company producing simulation software
- Retailer of luxury handbags
- Infrastructure software company
- Entertain and sports company
- A defense company
- Aluminum fabricator
- A biotech producing treatments for psoriasis
- A biotech finding cures for rare and rheumatic diseases
- A company providing value based healthcare
You Too Can Make A Fortune
This post was just published on ZYX Buy Change Alert.
Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.
Please click here to take advantage of a FREE 30 day trial.
Nigam Arora
Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.
Dr. Natasha Arora
Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.
